{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:53:57Z","timestamp":1773449637145,"version":"3.50.1"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The distribution of the three currently available lipid formulations of amphotericin B (AmB) into bone marrow and fat tissue was evaluated in noninfected rabbits. Groups of four animals each received either 1 mg of AmB deoxycholate (D-AmB) per kg of body weight per day or 5 mg of AmB colloidal dispersion, AmB lipid complex, or liposomal AmB per kg per day for seven doses. Plasma, bone marrow, fat, and liver were collected at autopsy, and AmB concentrations were determined by high-performance liquid chromatography. At the investigated dosages of 5 mg\/kg\/day, all AmB lipid formulations achieved at least fourfold-higher concentrations in bone marrow than did standard D-AmB at a dosage of 1 mg\/kg\/day. Concentrations in bone marrow were 62 to 76% of concurrent AmB concentrations in the liver. In contrast, all AmB formulations accumulated comparatively poorly in fat tissue. The results of this study show that high concentrations of AmB can be achieved in the bone marrow after administration of lipid formulations, suggesting their particular usefulness against disseminated fungal infections involving the bone marrow and against visceral leishmaniasis.<\/jats:p>","DOI":"10.1128\/aac.44.2.408-410.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"408-410","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits"],"prefix":"10.1128","volume":"44","author":[{"given":"Andreas H.","family":"Groll","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Mickiene","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmacokinetics Research Laboratory, Pharmacy Department, Warren Grant Magnuson Clinical Center,2 National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.518"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.684"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.4.512"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0378-4347(87)80307-9","article-title":"High-performance liquid chromatographic determination of amphotericin B in human serum.","volume":"419","author":"Brassinne C.","year":"1987","unstructured":"Brassinne C. Laduron C. Coune A. Sculier J. P. Hollaert C. Collette N. Meunier F. High-performance liquid chromatographic determination of amphotericin B in human serum. J. Chromatogr. 419 1987 401 407","journal-title":"J. Chromatogr."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.615"},{"key":"e_1_3_2_7_2","unstructured":"Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Commission on Life Sciences National Research Council\n          Guide for the care and use of laboratory animals.\n          1996\n          National Academy Press\n          Washington D.C."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00003495-199856060-00005","article-title":"Practical guide for the treatment of leishmaniasis.","volume":"56","author":"Davidson R. N.","year":"1998","unstructured":"Davidson R. N. Practical guide for the treatment of leishmaniasis. Drugs 56 1998 1009 1018","journal-title":"Drugs"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.356"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60129-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions.","volume":"22","author":"Hiemenz J. W.","year":"1996","unstructured":"Hiemenz J. W. Walsh T. J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 (Suppl. 2) 1996 S133 S144","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B.","volume":"23","author":"Janknegt R.","year":"1992","unstructured":"Janknegt R. de Marie S. Bakker-Woudenberg I. A. J. M. Crommelin D. J. A. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23 1992 279 291","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2125.1989.tb03529.x","article-title":"Gentamicin volume of distribution as a power function of body weight.","volume":"28","author":"Keller F.","year":"1989","unstructured":"Keller F. Gentamicin volume of distribution as a power function of body weight. Br. J. Clin. Pharmacol. 28 1989 479 481","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.713"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2089"},{"key":"e_1_3_2_16_2","first-page":"1576","article-title":"Use of liposomes as injectable drug delivery systems.","volume":"46","author":"Ostro M. J.","year":"1989","unstructured":"Ostro M. J. Cullis P. R. Use of liposomes as injectable drug delivery systems. Am. J. Hosp. Pharm. 46 1989 1576 1587","journal-title":"Am. J. Hosp. Pharm."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/28.suppl_B.49","article-title":"Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents.","volume":"28","author":"Proffitt R. T.","year":"1991","unstructured":"Proffitt R. T. Satorius A. Chiang S. M. Sullivan L. Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (Suppl. B) 1991 49 61","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/infdis\/138.4.499","article-title":"A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects.","volume":"138","author":"Schwartz S. N.","year":"1978","unstructured":"Schwartz S. N. Pazin G. J. Lyon J. A. Ho M. Pasculle A. W. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J. Infect. Dis. 138 1978 499 505","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/j.1552-4604.1981.tb01769.x","article-title":"Effect of obesity on gentamicin pharmacokinetics.","volume":"21","author":"Sketris I.","year":"1981","unstructured":"Sketris I. Lesar T. Zaske D. E. Cipolle R. J. Effect of obesity on gentamicin pharmacokinetics. J. Clin. Pharmacol. 21 1981 288 293","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_3_2_20_2","first-page":"467","article-title":"Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits.","volume":"38","author":"Walsh T. J.","year":"1988","unstructured":"Walsh T. J. Bacher T. Pizzo P. A. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38 1988 467 470","journal-title":"Lab. Anim. Med."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/ajcp\/79.4.509","article-title":"Disseminated histoplasmosis complicating bone marrow transplantation.","volume":"79","author":"Walsh T. J.","year":"1983","unstructured":"Walsh T. J. Catchatourian R. Cohen H. Disseminated histoplasmosis complicating bone marrow transplantation. Am. J. Clin. Pathol. 79 1983 509 511","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1016243313027","article-title":"Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats.","volume":"12","author":"Wang L. H.","year":"1995","unstructured":"Wang L. H. Fielding R. M. Smith P. C. Guo L. S. S. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm. Res. 12 1995 275 283","journal-title":"Pharm. Res."},{"key":"e_1_3_2_23_2","first-page":"7","article-title":"Histoplasmosis in the acquired immunodeficiency syndrome.","volume":"7","author":"Wheat J.","year":"1995","unstructured":"Wheat J. Histoplasmosis in the acquired immunodeficiency syndrome. Curr. Top. Med. Mycol. 7 1995 7 18","journal-title":"Curr. Top. Med. Mycol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.2.408-410.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.2.408-410.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:33:58Z","timestamp":1645461238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.2.408-410.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1128\/AAC.44.2.408-410.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.2.408-410.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]},"assertion":[{"value":"1999-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}